Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2023-01-26 Regulatory Filings
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Renalytix and Partners Awarded $10 Million Grant
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated January 26, 2023. It announces a significant event: Renalytix and partners being awarded a $10 Million Horizon Europe Grant to advance personalized medicine. The text is structured as a press release, detailing the news, quoting executives, listing partners, and concluding with standard 'About' sections and 'Forward Looking Statements'. The presence of the RNS header and the nature of the announcement (a specific, material corporate event update) strongly indicate this is a regulatory news service release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement, the most appropriate classification is the general regulatory announcement category, RNS.
2023-01-26 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1930 characters) and contains the header 'RNS Number : 1089M' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard shareholder communication (like DEF 14A or AGM-R). Since it is a general regulatory announcement disseminated via the RNS system that doesn't fit into the more specific categories (like DIRS, DIV, or DLST), it falls best under the general Regulatory Filings category (RNS) as a miscellaneous regulatory update.
2023-01-09 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1913 characters) and contains the header 'RNS Number : 1075M' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, brief operational announcement related to trading mechanics, not a comprehensive financial report or a standard regulatory filing like 10-K or IR. Since it is a specific, non-standard regulatory announcement distributed via the RNS system, and it doesn't fit into the other specific categories (like DIV, ER, or DIRS), the most appropriate classification is the general regulatory announcement fallback category, RNS.
2023-01-09 English
Completes Agreement with Veterans Administration
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number' and contains standard boilerplate language associated with regulatory news services, specifically mentioning 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content is a press release announcing a significant business development: the execution of a Co-operative Research and Development Agreement (CRADA) with the Veterans Administration regarding the KidneyIntelX testing solution. This is a material corporate announcement, but it is not a full financial report (like 10-K or IR), a transcript (CT), or a specific regulatory filing form. Since it is a general, material announcement distributed via the RNS system that doesn't fit the other specific categories (like ER, DIV, CAP, etc.), the most appropriate classification is the general regulatory announcement fallback category, RNS.
2023-01-09 English
Group of companies' accounts made up to 2022-06-30
Regulatory Filings
2022-12-30 English
Result of AGM
AGM Information Classification · 99% confidence The document explicitly states it is announcing the 'Result of AGM' (Annual General Meeting) held on December 19, 2022. It provides a detailed table showing the vote counts ('In Favour', 'Against', 'Withheld') for each resolution presented at the AGM. This content directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, specifically including the results of voting.
2022-12-19 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.